Alcohol and HER2 polymorphisms as risk factor for cardiotoxicity in breast cancer treated with trastuzumab

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2569-2576

  Lemieux, Julie ^a,b,c   Diorio, Caroline ^a,c   Cǒté, Marc André ^a,c   Provencher, Louise ^a,c   Barabé, Frédéric ^b,c,d   Jacob, Simon ^a   St Pierre, Christine ^a   Demers, Éric ^a   Tremblay Lemay, Rosemarie ^a   Nadeau Larochelle, Corinne ^a   Michaud, Annick ^a   Laflamme, Christian ^a  

^a LAVAL UNIVERSITY   (Canada)

^b Oncology University Center   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

Alcohol; Cardiac risk factors; HER2 polymorphism; Trastuzumab

Indexed keywords

ALANINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ISOLEUCINE; PROLINE; TRASTUZUMAB; VALINE; ALCOHOL; ANTINEOPLASTIC AGENT; CARDIOTOXIN; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ALCOHOL CONSUMPTION; BREAST CANCER; CARDIOTOXICITY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOTE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; ARTICLE; BREAST TUMOR; CARDIAC RISK FACTORS; CHEMICALLY INDUCED DISORDER; DRINKING BEHAVIOR; DRUG EFFECT; GENETICS; HEART; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HER2 POLYMORPHISM; METABOLISM; MIDDLE AGED; PROTO ONCOGENE; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ALCOHOL; CARDIAC RISK FACTORS; HER2 POLYMORPHISM; TRASTUZUMAB;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOL DRINKING; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARDIOTOXINS; COHORT STUDIES; FEMALE; GENES, ERBB-2; GENOTYPE; HEART; HEART DISEASES; HEART FAILURE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; QUESTIONNAIRES; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK FACTORS; VENTRICULAR FUNCTION, LEFT;

MLCS; MLOWN;

EID: 84881323931     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Lal P, Tan LK and Chen B: Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123: 541-546, 2005.
2. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM and Hortobagyi GN: The HER2 receptor and breast cancer: Ten years of targeted anti-HER2 therapy and personalized medicine. Oncologist 14: 320-368, 2009.
3. Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V and Guarneri V: Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4: CD006243, 2012.
4. Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C et al: Trastuzumab-Associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25: 3859-3865, 2007.
5. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr., Ewer M, Keefe D et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23: 7811-7819, 2005.
6. Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A et al: Cardiac management during adjuvant trastuzumabtherapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 15: 24-35, 2008.
7. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C and Whelton PK: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161: 996-1002, 2001.
8. Rastogi P, Jeong J and Geyer CE: Five year update of cardiac dysfunction in NSABP B-31: a randomized trial of AC-paclitaxel vs. AC-paclitaxel with trastuzumab in HER2-positive, node positive, operable breast cancer. Proc Am Soc Clin Oncol 25: (Abst LBA513), 2007.
9. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al.: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26: 1231-1238, 2008.
10. Mill CP, Chester JA and Riese DJ: EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Can 1: 31-38, 2009.
11. Gavazzi A, De Maria R, Parolini M and Porcu M: Alcohol abuse and dilated cardiomyopathy in men. Am J Cardiol 85: 1114-1118, 2000.
12. Kloner RA and Rezkalla SH: To drink or not to drink? That is the question. Circulation 116: 1306-1317, 2007.
13. Fernandez-Sola J, Estruch R, Nicolas JM, Pare JC, Sacanella E, Antunez E et al: Comparison of alcoholic cardiomyopathy in women versus men. Am J Cardiol 80: 481-485, 1997.
14. Urbano-Marquez A, Estruch R, Fernandez-Sola J, Nicolas JM, Pare JC and Rubin E: The greater risk of alcoholic cardiomyopathy and myopathy in women compared with men. JAMA 274: 149-154, 1995.
15. Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E et al: Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumabrelated cardiotoxicity. Ann Oncol 18: 1335-1341, 2007.
16. Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, and Liu Y: ERBB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-465, 2002.
17. Papewalis J, Nikitin AY and Rajewsky MF: G to A polymorphism at amino acid codon 655 of the human ERBB-2/HER2 gene. Nucleic Acids Res 19: 5452, 1991.
18. Han W, Kang D, Lee JE, Park IA, Choi JY, Lee KM, et al.: A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea. Clin cancer res 11: 4775-4778, 2005.
19. Cresti N JD, Verrill MW, Pinkilgton M and Boddy AV: Fcγ-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab. J Clin Oncol 29: (Abst 565) 2011
20. Mailliez A RF, Ploquin A, Servent V and Bonneterre J: Trastuzumab Cardiac Toxicity and HER2 Polymorphism: A Case-Control Study. Cancer Res 70: (Abst P3-14-11) 2010.
21. Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM et al: The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2 -therapy. Can J Cardiol 24: 465-475, 2008.
22. Dawson DA: Methodological issues in measuring alcohol use. Alcohol Res Health 27: 18-29, 2003.
23. Gagnon JF, Sanschagrin F, Jacob S, Tremblay AA, Provencher L, Robert J et al: Quantitative DNA methylation analysis of laser capture microdissected formalin-fixed and paraffin-embedded tissues. Exp Mol Pathol 88: 184-189, 2010.
24. Benusiglio PR, Lesueur F, Luccarini C, Conroy DM, Shah M, Easton DF et al: Common ERBB2 polymorphisms and risk of breast cancer in a white British population: A case control study. Breast Cancer Res 7: 204-2099, 2005.
25. Ma Y, Yang J, Zhang P, Liu Z, Yang Z, and Qin H: Lack of association between HER2 codon 655 polymorphism and breast cancer susceptibility: meta-Analysis of 22 studies involving 19,341 subjects. Breast Cancer Res Treat 125: 237-241, 2011.
26. Tommasi S, Fedele V, Lacalamita R, Bruno M, Schittulli F, Ginzinger D et al: 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations. Cell Oncol 29: 241-248, 2007.
27. World Cancer Research Fund. American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Persepctive. Washington DC, 2007.
28. Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD et al: Management of cardiac health in trastuzumabtreated patients with breast cancer: Updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100: 684-692, 2009.
29. Di Cosimo S: Heart to heart with trastuzumab: A review on cardiac toxicity. Target Oncol 6: 189-195, 2011.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
31. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365: 1273-1283, 2011.
32. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672, 2005.
33. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr., Davidson NE et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005.
34. Slamon D, Eiermann W and Robert N: Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide follwoed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 94: S5a, 2005.
35. Wadhwa D, Fallah-Rad N, Grenier D, Krahn M, Fang T, Ahmadie R et al: Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: A retrospective study. Breast Cancer Res Treat 117: 357-364, 2009.
36. McArthur HL and Chia S: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 357: 94-95, 2007.
37. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR et al: Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol 24: 4107-4115, 2006.
38. Vicente C, Serrano N, Agustin MJ, Alonso V, Palomo P and Huarte R: Cardiotoxicity associated with trastuzumab in normal clinical practice. Farm Hosp 33: 202-207, 2009.
39. Letarte N, Marcotte N and Michel M: Review of utilization of trastuzumab in the adjuvant treatment of breast cancer in four university teaching hospitals in Quebec, Canada. J Clin Oncol 26(Suppl): 6615, 2008.
40. Ewer MS, Vooletich MT, Durand JB, Woods ML, Davis JR, Valero V et al: Reversibility of trastuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 23: 7820-7826, 2005.
41. Murray LJ, Ramakrishnan S, O'Toole L, Manifold IH, Purohit OP and Coleman RE: Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. Breast 19: 339-344, 2010.
42. Khoury MJ, Beaty TH and Cohen BH: Fundamentals of genetic epidemiology. New York: Oxford University Press, 1993.
43. Rothman KJ and Greenland S: Modern Epidemiology. Philadelphia: Lippincott-Raven, 1998.
44. Rothman N, Wacholder S, Caporaso NE, Garcia-Closas M, Buetow K and Fraumeni JF Jr.: The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim Biophys Acta 1471: 1-10, 2001.
45. Wacholder S, Rothman N and Caporaso N: Counterpoint: Bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev 11: 513-520, 2002.
46. Cardon LR and Palmer LJ: Population stratification and spurious allelic association. Lancet 361: 598-604, 2003.
47. Kwan ML, Kushi LH, Weltzien E, Tam EK, Castillo A, Sweeney C et al: Alcohol consumption and breast cancer recurrence and survival among women with early-stage breast cancer: The Life after Cancer Epidemiology Study. J Clin Oncol 28: 4410-4416, 2010.